Compare BioNTech SE - ADR (BNTX) vs Teradyne, Inc. (TER) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNTech SE - ADR vs Teradyne, Inc. — how do they compare? BioNTech SE - ADR trades at $93.42 (market cap $23.31B), while Teradyne, Inc. trades at $401.64 (market cap $59.34B). The key difference: Teradyne, Inc. is far larger — about 2.5× BioNTech SE - ADR's market cap, and Teradyne, Inc. pays a 0.14% dividend while BioNTech SE - ADR pays none. Which is the better fit depends on your goals.
| BNTX | TER | |
|---|---|---|
Market Cap | $23.31B | $59.34B |
Sector | Health | Technology |
52-Week High | $119.34 | $483.84 |
52-Week Low | $83.89 | $109.30 |
Enterprise Value | $6.60B | $59.09B |
Dividend Yield | — | 0.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $93.27, up 0.51% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported Q2 2026 revenue of $106 million, missing expectations, and lowered its full-year sales outlook due to weak COVID-19 vaccine demand. Despite negative net income margins and cash outflows, BNTX maintains a strong cash position of $16.78 billion and is advancing its oncology pipeline with 14 pivotal clinical trials.
The outlook is mixed: analyst consensus is strongly bullish with a $121 price target, but declining COVID revenue and ongoing losses pose significant risks. Investment opportunity hinges on successful pipeline development, while near-term headwinds from vaccine demand softness and leadership transition require careful monitoring.
Teradyne (TER) trades at $403.6, up 10.55% in 24 hours, near its 52-week high. The stock exhibits bullish technical signals with strong earnings beats in recent quarters, including Q2 2026 EPS of $2.47 versus $2.09 expected. Revenue growth is accelerating, driven by AI-led demand in semiconductor testing and robotics, with 2026 revenue projected at $4.5 billion. Valuation ratios are elevated, with a P/E of 52.14, reflecting high growth expectations.
The outlook remains positive due to robust AI-driven demand and record earnings, though high valuation poses a risk if growth slows. Analyst consensus is strongly bullish with a $481.63 price target. Key risks include execution challenges in scaling operations and sensitivity to semiconductor cycle downturns. Institutional buying, such as Anson Funds' purchase in Q1 2026, supports momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →About Teradyne, Inc.
Teradyne provides testing equipment, including automated test equipment for semiconductors, system testing for hard disk drives, circuit boards, and electronics systems and wireless testing for devices. The firm entered the industrial automation market in 2015, into which it sells collaborative and autonomous robots for factory applications. Teradyne serves numerous end markets and geographies directly and indirectly with its products, but its most significant exposure is to semiconductor testing, which made up 71% of 2021 sales. Teradyne serves vertically integrated, fabless, and foundry chipmakers with its equipment.
Read more on TER →
